# DYADIC INTERNATIONAL INC (DYAI) · Edgar & Edgarette company card

> Dyadic International (DYAI) saw revenue fall 11.6% in FY2025 to $3 million, operating margin -233% against a -15.8% median for biological products, (no diagnostic substances), equity 12.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1213809 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/DYAI) · [JSON](https://www.pops4.com/boards/company/DYAI.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $3M |
| Revenue growth, 1 year | -11.6% |
| Revenue growth per year | 6.5% |
| Operating margin | -232.8% (prior year -168.8%) |
| Net margin | -238.3% |
| Operating cash flow | −$6M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $5M |
| Long-term debt | — |
| Total assets | $10M |
| Total equity | $1M |
| Equity ÷ assets | 12.4% |
| Return on equity | -597.6% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -31.25 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -232.8% in FY2025; revenue is hard to predict: its 80% range is ±44%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $3.1M (FY2025). Experience: revenue down 11.6% on the year, up 6.5% a year over 4 years; operating margin -232.8%, down from -168.8%. Soundness: equity 12.4% of assets, return on equity -597.6%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1.8M and $4.6M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $1.7M to $4.9M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -232.8% against a -15.8% median; growth -11.6% against 21.4%.

Range logged 2026-09-24, receipt 24d78f8296cf3f26, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 4, latest 2026-09-25 ([filing](https://www.sec.gov/Archives/edgar/data/1213809/000149315226044398/0001493152-26-044398-index.htm))

## Recent filings

- 8-K · filed 2026-09-25 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule · [filing](https://www.sec.gov/Archives/edgar/data/1213809/000149315226044398/0001493152-26-044398-index.htm)
- S-1 · filed 2026-09-11 · [filing](https://www.sec.gov/Archives/edgar/data/1213809/000149315226042435/0001493152-26-042435-index.htm)
- 8-K · filed 2026-08-14 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1213809/000149315226038039/0001493152-26-038039-index.htm)
- 10-Q · filed 2026-08-12 · [filing](https://www.sec.gov/Archives/edgar/data/1213809/000149315226037258/0001493152-26-037258-index.htm)
- 8-K · filed 2026-08-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1213809/000149315226037257/0001493152-26-037257-index.htm)
- 8-K · filed 2026-07-24 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1213809/000149315226034475/0001493152-26-034475-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001213809.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1213809

## Cite

POPS4, Edgar & Edgarette: DYADIC INTERNATIONAL INC (DYAI) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/DYAI. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.